Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP1363051.RAM4HdZgQCuHf4Z_waQajdE2Jppzva3h9Cy2fttIhOy90130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP1363051.RAM4HdZgQCuHf4Z_waQajdE2Jppzva3h9Cy2fttIhOy90130_assertion type Assertion NP1363051.RAM4HdZgQCuHf4Z_waQajdE2Jppzva3h9Cy2fttIhOy90130_head.
- NP1363051.RAM4HdZgQCuHf4Z_waQajdE2Jppzva3h9Cy2fttIhOy90130_assertion description "[Moreover, secondary acute myeloid leukemias (AML) that occur as the result of chemotherapy agents, which are known to inhibit DNA topoisomerase II, often manifest the same MLL abnormalities.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1363051.RAM4HdZgQCuHf4Z_waQajdE2Jppzva3h9Cy2fttIhOy90130_provenance.
- NP1363051.RAM4HdZgQCuHf4Z_waQajdE2Jppzva3h9Cy2fttIhOy90130_assertion evidence source_evidence_literature NP1363051.RAM4HdZgQCuHf4Z_waQajdE2Jppzva3h9Cy2fttIhOy90130_provenance.
- NP1363051.RAM4HdZgQCuHf4Z_waQajdE2Jppzva3h9Cy2fttIhOy90130_assertion SIO_000772 8932918 NP1363051.RAM4HdZgQCuHf4Z_waQajdE2Jppzva3h9Cy2fttIhOy90130_provenance.
- NP1363051.RAM4HdZgQCuHf4Z_waQajdE2Jppzva3h9Cy2fttIhOy90130_assertion wasDerivedFrom befree-2016 NP1363051.RAM4HdZgQCuHf4Z_waQajdE2Jppzva3h9Cy2fttIhOy90130_provenance.
- NP1363051.RAM4HdZgQCuHf4Z_waQajdE2Jppzva3h9Cy2fttIhOy90130_assertion wasGeneratedBy ECO_0000203 NP1363051.RAM4HdZgQCuHf4Z_waQajdE2Jppzva3h9Cy2fttIhOy90130_provenance.